• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高三尖杉酯碱在犬体内的药代动力学

Pharmacokinetics of homoharringtonine in dogs.

作者信息

Lu K, Savaraj N, Feun L G, Guo Z G, Umsawasdi T, Loo T L

机构信息

Division of Medicine, University of Texas M. D. Anderson Hospital and Tumor Institute, Houston.

出版信息

Cancer Chemother Pharmacol. 1988;21(2):139-42. doi: 10.1007/BF00257360.

DOI:10.1007/BF00257360
PMID:3349562
Abstract

We studied the pharmacokinetics and distribution of homoharringtonine (HHT), an antitumor alkaloid, in anesthetized dogs using chromatographic and radiochemical techniques. Uniformly tritiated HHT was administered i.v. to five dogs at doses of 0.05 to 0.34 mg/kg, 200 microCi per animal. Unchanged HHT disappeared in a triphasic manner from the plasma with an initial plasma t1/2 of 9.4 +/- 4.2 min, an intermediary t1/2 of 1.4 +/- 0.5 h, and a terminal t1/2 of 40.6 +/- 4.6 h. The plasma clearance was 114.0 +/- 20.1 ml/kg-1 h-1 and the steady-state volume of distribution was 6.2 +/- 0.7 1/kg. In 72 h, 40.1% +/- 4.0% of the administered radioactivity was excreted in the urine, 17.8% +/- 2.7% of which was unchanged HHT. HHT was metabolized extensively to one major and two minor metabolites. Biliary excretion of total radioactivity was 14.4% in 5 h, 2% of which was HHT. HHT concentration in the CSF was highest 4 h after drug administration, about 40% of the concentration in the concurrent plasma. At autopsy 5 h after dosing, the highest percentage of HHT was in the liver (7.4%), followed by the small intestine (2.5%), stomach (1.0%), pancreas (0.8%), kidneys (0.8%), and lungs (0.7%). The heart, spleen, large intestine, and brain each retained less than 0.5%. However, 24 h after dosing, 4% of the HHT still remained in the liver, 1% in the small intestine, and less than 1% in the other organs. HHT seems to be extensively metabolized in dogs and partially retained in the body.

摘要

我们采用色谱和放射化学技术,研究了抗肿瘤生物碱高三尖杉酯碱(HHT)在麻醉犬体内的药代动力学和分布情况。将均匀标记有氚的HHT以每只动物200微居里的剂量静脉注射给5只犬,剂量为0.05至0.34毫克/千克。原形HHT以三相方式从血浆中消失,初始血浆半衰期为9.4±4.2分钟,中间半衰期为1.4±0.5小时,终末半衰期为40.6±4.6小时。血浆清除率为114.0±20.1毫升/千克-1小时-1,稳态分布容积为6.2±0.7升/千克。在72小时内,给药放射性的40.1%±4.0%经尿液排泄,其中17.8%±2.7%为原形HHT。HHT被广泛代谢为一种主要代谢物和两种次要代谢物。5小时内总放射性的胆汁排泄率为14.4%,其中2%为HHT。给药后4小时脑脊液中HHT浓度最高,约为同时期血浆浓度的40%。给药后5小时尸检时,HHT含量最高的是肝脏(7.4%),其次是小肠(2.5%)、胃(1.0%)、胰腺(0.8%)、肾脏(0.8%)和肺(0.7%)。心脏、脾脏、大肠和大脑中的含量均低于0.5%。然而,给药后24小时,肝脏中仍有4%的HHT,小肠中有1%,其他器官中不到1%。HHT在犬体内似乎被广泛代谢且部分留存于体内。

相似文献

1
Pharmacokinetics of homoharringtonine in dogs.高三尖杉酯碱在犬体内的药代动力学
Cancer Chemother Pharmacol. 1988;21(2):139-42. doi: 10.1007/BF00257360.
2
Pharmacokinetics of Amonafide in dogs.氨萘非特在犬体内的药代动力学
Cancer Chemother Pharmacol. 1988;21(2):134-8. doi: 10.1007/BF00257359.
3
Central nervous system (CNS) penetration of homoharringtonine (HHT).高三尖杉酯碱(HHT)对中枢神经系统(CNS)的穿透性。
J Neurooncol. 1987;5(1):77-81. doi: 10.1007/BF00162769.
4
Clinical pharmacology of homoharringtonine.高三尖杉酯碱的临床药理学
Cancer Treat Rep. 1986 Dec;70(12):1403-7.
5
Pharmacokinetics, distribution, metabolism and excretion of.
Cancer Chemother Pharmacol. 2001;47(2):106-12. doi: 10.1007/s002800000213.
6
Pharmacological disposition of 1,4-dihydroxy-5-8-bis[[2 [(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione dihydrochloride in the dog.1,4 - 二羟基 - 5,8 - 双[[2 - [(2 - 羟乙基)氨基]乙基]氨基] - 9,10 - 蒽二酮二盐酸盐在犬体内的药物处置
Cancer Chemother Pharmacol. 1984;13(1):63-6. doi: 10.1007/BF00401450.
7
Metabolism of homoharringtonine, a cytotoxic component of the evergreen plant Cephalotaxus harringtonia.高三尖杉酯碱的代谢,高三尖杉酯碱是常绿植物三尖杉中的一种细胞毒性成分。
J Exp Ther Oncol. 2003 Jan-Feb;3(1):47-52. doi: 10.1046/j.1359-4117.2003.01066.x.
8
Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs.新型抗癌药物酒石酸长春瑞滨在小鼠、大鼠和犬静脉注射后的处置情况。
Arzneimittelforschung. 1993 Dec;43(12):1367-77.
9
The pharmacologic fate of the antitumor agent 2-amino-1,3,4-thiadiazole in the dog.抗肿瘤药物2-氨基-1,3,4-噻二唑在犬体内的药理转归
Cancer Chemother Pharmacol. 1980;4(4):275-9. doi: 10.1007/BF00255274.
10
Pharmacological disposition of 1,4-bis (2-[(2-hydroxyethyl)amino]-ethylamino)-9,10-anthracenedione diacetate in the dog.1,4-双(2-[(2-羟乙基)氨基]乙基氨基)-9,10-蒽二酮二乙酸酯在犬体内的药物处置情况
Cancer Res. 1980 May;40(5):1427-30.

引用本文的文献

1
Preclinical evaluation of protein synthesis inhibitor omacetaxine in pediatric brainstem gliomas.蛋白合成抑制剂奥马西他辛在小儿脑干胶质瘤中的临床前评估
Neurooncol Adv. 2024 Mar 16;6(1):vdae029. doi: 10.1093/noajnl/vdae029. eCollection 2024 Jan-Dec.
2
Pharmacokinetics and excretion of (14)C-omacetaxine in patients with advanced solid tumors.晚期实体瘤患者中(14)C-奥马西他辛的药代动力学与排泄
Invest New Drugs. 2016 Oct;34(5):565-74. doi: 10.1007/s10637-016-0360-9. Epub 2016 May 25.
3
Altering chemosensitivity by modulating translation elongation.

本文引用的文献

1
Phase I clinical investigation of homoharringtonine.高三尖杉酯碱的I期临床研究。
Cancer Treat Rep. 1984 Sep;68(9):1085-91.
2
Antitumor alkaloids for Cephalataxus harringtonia: structure and activity.
J Pharm Sci. 1972 Aug;61(8):1227-30. doi: 10.1002/jps.2600610812.
3
Homoharringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukemia.高三尖杉酯碱:一种用于难治性非淋巴细胞白血病诱导缓解的有效新药。
J Clin Oncol. 1985 May;3(5):617-21. doi: 10.1200/JCO.1985.3.5.617.
通过调节翻译延伸来改变化学敏感性。
PLoS One. 2009;4(5):e5428. doi: 10.1371/journal.pone.0005428. Epub 2009 May 1.
4
Clinical pharmacology of homoharringtonine.高三尖杉酯碱的临床药理学
Cancer Treat Rep. 1986 Dec;70(12):1403-7.
5
Harringtonine, an inhibitor of initiation of protein biosynthesis.高三尖杉酯碱,一种蛋白质生物合成起始的抑制剂。
Mol Pharmacol. 1975 Sep;11(5):511-9.
6
Inhibition of protein synthesis in intact HeLa cells.完整HeLa细胞中蛋白质合成的抑制作用。
Antimicrob Agents Chemother. 1975 Oct;8(4):479-87. doi: 10.1128/AAC.8.4.479.
7
Cephalotaxine esters in the treatment of acute leukemia. A preliminary clinical assessment.三尖杉酯碱治疗急性白血病的初步临床评价
Chin Med J (Engl). 1976 Jul;2(4):263-72.